<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825194/" ref="ordinalpos=1285&amp;ncbi_uid=5493460&amp;link_uid=PMC3825194" image-link="/pmc/articles/PMC3825194/figure/F001/" class="imagepopup">Fig. 1.TGF-β <span class="highlight" style="background-color:">signaling</span> through Smad-dependent and Smad-independent pathways. (A) Canonical <span class="highlight" style="background-color:">pathway</span>. TGF-β ligands activated TGF- βRI and TGF-βRII receptor complex recruits and phosphorylates the receptor specific Smad2/3. Hetero-oligomeric complex of Smad2/3- Smad4 translocates to the nucleus and binds to specific DNA sequence and interacts with transcription factors and cofactors to regulate transcription. The <span class="highlight" style="background-color:">pathway</span> is negatively regulated by the Smad6/7, which bind activated TGF-βRI, thereby preventing phosphorylation of Smad2/3, or recruit the E3 ubiquitine ligases to induce proteasomal degradation of the Smad2/3 (B) Noncanonical <span class="highlight" style="background-color:">pathway</span>. Smad-independent <span class="highlight" style="background-color:">signaling</span>. TGF-β can promote the activity of several <span class="highlight" style="background-color:">signaling</span> pathways other than Smad, including MAPKs, PI3K kinases, TRAF6- TAK1-p38/JNK, Rho-Rock, among others..  From: Targeting the Transforming Growth Factor-? <span class="highlight" style="background-color:">Signaling</span> in Cancer Therapy. </a></div><br /><div class="p4l_captionBody"></div></div>